申请人:Eli Lilly and Company
公开号:US06140352A1
公开(公告)日:2000-10-31
Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: ##STR1## The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.
本文披露了由以下结构式表示的选择性β3肾上腺素能激动剂:##STR1## 上述结构式中的变量在说明书中有定义。还披露了使用这些化合物来激动β3肾上腺素能受体的方法,例如,需要此类治疗的患者,例如需要肥胖或2型糖尿病治疗的患者。